Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE).

Autor: Sabhan H; Gastroenterology Unit, Medical Department, Capio St Göran Hospital., Bello F; Division of Gastroenterology, Medical Department, Karolinska University Hospital, Stockholm., Muhsen S; Department of Medicine, Division of Gastroenterology and Hepatology, Danderyd Hospital, Danderyd., Borin A; Department of Medicine, South Hospital, Stockholm., Johansson F; Medical Library at Danderyd Hospital, Danderyd., Höög C; Division of Gastroenterology, Medical Department, Karolinska University Hospital, Stockholm.; Department of Medicine, Karolinska Institutet, Huddinge., Forsberg O; Janssen Cilag AB., Wennerström C; Janssen Cilag AB., Lördal M; Department of Medicine, Division of Gastroenterology and Hepatology, Danderyd Hospital, Danderyd., Almer S; Division of Gastroenterology, Medical Department, Karolinska University Hospital, Stockholm.; Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden., Söderman C; Gastroenterology Unit, Medical Department, Capio St Göran Hospital.; Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden.

Publikováno v: European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2024 Dec 01; Vol. 36 (12), pp. 1419-1425. Date of Electronic Publication: 2024 Sep 20.

Long-term real-world data of ustekinumab in Crohn's disease: the Stockholm ustekinumab study.

Autor: Bello F; Karolinska Institutet, Department of Medicine Solna, Karolinska University Hospital, Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden., Muhsen S; Division of Gastroenterology and Hepatology, Department of Medicine, Danderyd Hospital, Danderyd, Sweden., Sabhan H; Gastroenterology Unit, Medical Department, St Göran's Hospital, Stockholm, Sweden., Borin A; Department of Medicine, South Hospital, Stockholm, Sweden., Johansson F; Medical Library at Danderyd Hospital, Danderyd, Sweden., Höög C; Department of Upper Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Forsberg O; Janssen-Cilag AB, Stockholm, Sweden., Wennerström C; Janssen-Cilag AB, Stockholm, Sweden., Söderman C; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden Gastroenterology Unit, Medical Department, St Göran's Hospital, Stockholm, Sweden., Lördal M; Division of Gastroenterology and Hepatology, Department of Medicine, Danderyd Hospital, Danderyd, Sweden., Almer S; Karolinska Institutet, Department of Medicine Solna, Karolinska University Hospital, Centre for Digestive Health, Department of Gastroenterology B4:09, Dermatovenereology and Rheumatology, SE-171 76 Stockholm, Sweden.

Publikováno v: Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2024 Apr 23; Vol. 17, pp. 17562848241242700. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024).

Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.

Autor: Zhao M; Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark., Lirhus S; Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway., Lördal M; Division of Gastroenterology and Hepatology, Department of Medicine, Danderyds Hospital, Stockholm, Sweden., Langholz E; Gastro Unit, Medical Division, Herlev University Hospital, Herlev, Denmark.; Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Knudsen T; Department of Medicine, Hospital of South West Denmark, Esbjerg, Denmark.; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Voutilainen M; Department of Gastroenterology, University of Turku and Turku University Hospital, Turku, Finland., Høivik ML; Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Moum B; Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Anisdahl K; Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Saebø B; Takeda AS, Medical Affairs, Asker, Norway., Haiko P; Takeda Oy, Medical Affairs, Helsinki, Finland., Malmgren C; Takeda Pharma AB, Medical Affairs, Stockholm, Sweden., Coskun M; Takeda Pharma A/S, Medical Affairs, Vallensbaek Strand, Denmark., Melberg HO; Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway., Burisch J; Gastrounit, Medical Division, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark.

Publikováno v: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Sep; Vol. 56 (6), pp. 989-1006. Date of Electronic Publication: 2022 Jul 28.

Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease ^.

Autor: Hossain A; Department of Emergency and Reparative Medicine, Karolinska University Hospital, Stockholm, Sweden.; Department of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden., Lördal M; Department of Medicine, Division of Gastroenterology and Hepatology, Danderyds Hospital, Stockholm, Sweden., Olsson AE; Department of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden., Storlåhls A; Department of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden., Aleman S; Department of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden.; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Eberhardson M; Department of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden.; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Befrits R; Department of Gastroenterology, Karolinska University Hospital, Stockholm, Sweden.

Publikováno v: Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2020 Feb; Vol. 55 (2), pp. 178-183. Date of Electronic Publication: 2020 Feb 13.

A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine

Autor: Lördal, M., Navalesi, G., Elvar Theodorsson, Maggi, C. A., Hellström, P. M.

Publikováno v: Scopus-Elsevier

1. MEN 11420 (nepadutant) is a potent, selective and competitive antagonist of tachykinin NK2 receptors. 2. The objective of the present study was to assess the capability of the drug to antagonize the stimulatory effects of neurokinin A (NKA) on gas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::aeb9ce99677d7bb0c76c1aeab02dce05
https://europepmc.org/articles/PMC1572917/